HC Wainwright Has Negative Opinion of CRBP FY2026 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Stock analysts at HC Wainwright cut their FY2026 EPS estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now forecasts that the biopharmaceutical company will post earnings per share of ($6.61) for the year, down from their prior forecast of ($6.11). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($5.89) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q4 2026 earnings at ($1.73) EPS, FY2027 earnings at ($6.13) EPS, FY2028 earnings at ($5.28) EPS, FY2029 earnings at ($2.19) EPS and FY2030 earnings at ($0.09) EPS.

A number of other equities research analysts also recently commented on CRBP. Oppenheimer reaffirmed an “outperform” rating on shares of Corbus Pharmaceuticals in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Thursday, October 15th. Mizuho lowered their price target on Corbus Pharmaceuticals from $24.00 to $23.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Wall Street Zen downgraded Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $38.14.

Corbus Pharmaceuticals Stock Up 1.8%

Shares of Corbus Pharmaceuticals stock opened at $4.00 on Thursday. Corbus Pharmaceuticals has a twelve month low of $2.81 and a twelve month high of $12.88. The company’s 50 day moving average is $5.99 and its 200 day moving average is $8.40. The company has a market cap of $74.68 million, a price-to-earnings ratio of -0.66 and a beta of 2.80.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings data on Tuesday, November 10th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.54).

Insider Activity

In other news, major shareholder Cormorant Asset Management, Lp sold 425,000 shares of the company’s stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $4.10, for a total transaction of $1,742,500.00. Following the completion of the sale, the insider owned 1,919,971 shares of the company’s stock, valued at $7,871,881.10. This represents a 18.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Corbus Pharmaceuticals

Several institutional investors have recently made changes to their positions in CRBP. Ieq Capital LLC purchased a new position in shares of Corbus Pharmaceuticals in the third quarter worth approximately $96,000. Bank of America Corp DE grew its position in Corbus Pharmaceuticals by 53,592.3% during the first quarter. Bank of America Corp DE now owns 13,960 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 13,934 shares during the period. Pale Fire Capital SE grew its position in Corbus Pharmaceuticals by 14.5% during the first quarter. Pale Fire Capital SE now owns 21,350 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 2,700 shares during the period. Engineers Gate Manager LP grew its position in Corbus Pharmaceuticals by 109.9% during the second quarter. Engineers Gate Manager LP now owns 29,800 shares of the biopharmaceutical company’s stock valued at $280,000 after buying an additional 15,600 shares during the period. Finally, Royal Bank of Canada increased its holdings in Corbus Pharmaceuticals by 81.2% during the first quarter. Royal Bank of Canada now owns 29,901 shares of the biopharmaceutical company’s stock valued at $281,000 after buying an additional 13,401 shares during the last quarter. Institutional investors own 64.64% of the company’s stock.

Corbus Pharmaceuticals News Summary

Here’s some of the latest news about CRBP:

• Positive Sentiment: HC Wainwright raised its estimates for FY2027 and FY2028, forecasting losses of $6.13 and $5.28 per share, respectively. The firm maintained its Buy rating and $35 price target, which offers a counterpoint to the lowered estimates. Corbus Pharmaceuticals coverage
• Negative Sentiment: HC Wainwright cut its Q4 2026 and FY2026 estimates to losses of $1.73 and $6.61 per share, respectively. It also lowered FY2029 and FY2030 forecasts, with the latter shifting from expected earnings of $0.15 per share to a loss of $0.09. The downward revisions reinforce concerns about the company’s path to profitability. Corbus Pharmaceuticals coverage
• Negative Sentiment: Corbus reported a Q3 loss of $1.81 per share, wider than the $1.27 loss analysts expected—a miss of $0.54 per share. The earnings shortfall may add pressure to the stock. Q3 financial results and corporate update

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research is centered on therapies designed to modulate immune-cell activity and target biological pathways involved in cancer and inflammatory disease. Corbus’ oncology pipeline has included soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) being evaluated for its potential to treat T-cell lymphomas and other cancers.